156 related articles for article (PubMed ID: 15272064)
21. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
22. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
23. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
25. A Microtiter Plate Assay at Acidic pH to Identify Potentiators that Enhance Pyrazinamide Activity Against Mycobacterium tuberculosis.
Moon CW; Porges E; Taylor SC; Bacon J
Methods Mol Biol; 2024; 2833():65-77. PubMed ID: 38949702
[TBL] [Abstract][Full Text] [Related]
26. A novel inexpensive electrochemical sensor for pyrazinoic acid as a potential tool for the identification of pyrazinamide-resistant
Rueda D; Furukawa R; Fuentes P; Comina G; Rey De Castro NG; Requena D; Gilman RH; Sheen P; Zimic M
Int J Mycobacteriol; 2018; 7(3):275-281. PubMed ID: 30198510
[TBL] [Abstract][Full Text] [Related]
27. Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.
Naftalin CM; Verma R; Gurumurthy M; Lu Q; Zimmerman M; Yeo BCM; Tan KH; Lin W; Yu B; Dartois V; Paton NI
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739782
[TBL] [Abstract][Full Text] [Related]
28. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
29. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
30. [Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey].
Ozkütük N; Ecemiş T; Sürücüoğlu S
Mikrobiyol Bul; 2008 Oct; 42(4):585-90. PubMed ID: 19149079
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Gopal P; Grüber G; Dartois V; Dick T
Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
[TBL] [Abstract][Full Text] [Related]
32. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
33. The curious characteristics of pyrazinamide: a review.
Zhang Y; Mitchison D
Int J Tuberc Lung Dis; 2003 Jan; 7(1):6-21. PubMed ID: 12701830
[TBL] [Abstract][Full Text] [Related]
34. Correlation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital.
Fonseca Lde S; Marsico AG; Vieira GB; Duarte Rda S; Saad MH; Mello Fde C
J Bras Pneumol; 2012; 38(5):630-3. PubMed ID: 23147056
[TBL] [Abstract][Full Text] [Related]
35. Pyrazinamide triggers degradation of its target aspartate decarboxylase.
Gopal P; Sarathy JP; Yee M; Ragunathan P; Shin J; Bhushan S; Zhu J; Akopian T; Kandror O; Lim TK; Gengenbacher M; Lin Q; Rubin EJ; Grüber G; Dick T
Nat Commun; 2020 Apr; 11(1):1661. PubMed ID: 32245967
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.
Yang J; Liu Y; Bi J; Cai Q; Liao X; Li W; Guo C; Zhang Q; Lin T; Zhao Y; Wang H; Liu J; Zhang X; Lin D
Mol Microbiol; 2015 Mar; 95(5):791-803. PubMed ID: 25430994
[TBL] [Abstract][Full Text] [Related]
37. Estimation of pyrazinamidase activity using a cell-free
Rueda D; Bernard C; Gandy L; Capton E; Boudjelloul R; Brossier F; Veziris N; Zimic M; Sougakoff W
Int J Mycobacteriol; 2018; 7(1):16-25. PubMed ID: 29516881
[TBL] [Abstract][Full Text] [Related]
38. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
[TBL] [Abstract][Full Text] [Related]
39. Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide.
Santucci P; Greenwood DJ; Fearns A; Chen K; Jiang H; Gutierrez MG
Nat Commun; 2021 Jun; 12(1):3816. PubMed ID: 34155215
[TBL] [Abstract][Full Text] [Related]
40. Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.
den Hertog AL; Menting S; Pfeltz R; Warns M; Siddiqi SH; Anthony RM
Antimicrob Agents Chemother; 2016 Aug; 60(8):4956-60. PubMed ID: 27270287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
